Giapreza: Clinical Trials

4 trials of Giapreza, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 completed, 1 recruiting, 1 withdrawn. 4 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 24Active not recruiting 1, Completed 1, Recruiting 1, Withdrawn 1
Phase 31Active not recruiting 1

Follow Giapreza: new trials by email Literature Review of Giapreza trials Research Report on Giapreza

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)
Angiotensin II (Giapreza®), Yttrium-90 radioembolization - Liver Cancer (Locally Advanced or Metastatic), Liver Cancer Adult
Phase 2RecruitingNiek Wijnen152026-01-012026-03-30
Angiotensin II in Liver Transplantation
Angiotensin II, Saline - Liver Transplant; Complications, Vasoplegia
Phase 2 / Phase 3Active not recruitingUniversity of California, San Francisco502022-06-282026-03-20
Angiotensin 2 for Hepatorenal Syndrome
Angiotensin II, Midodrine, Octreotide - Hepatorenal Syndrome, Cirrhosis
Phase 2WithdrawnUniversity of California, Los Angeles2021-07-012024-03-06
A Study of LJPC-501 in Pediatric Patients With Hypotension
Angiotensin II - Catecholamine-resistant Hypotension (CRH), Distributive Shock
Phase 2CompletedLa Jolla Pharmaceutical Company22018-02-112018-08-07

Conditions studied

Acute Kidney Injury (2)  ·  Fibrosis (2)  ·  Carcinoma, Hepatocellular (1)  ·  Hepatorenal Syndrome (1)  ·  Hypotension (1)  ·  Liver Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Sepsis (1)  ·  Vasoplegia (1)

Sponsors

La Jolla Pharmaceutical Company (1)  ·  Niek Wijnen (1)  ·  University of California, Los Angeles (1)  ·  University of California, San Francisco (1)

Countries

United States (2)  ·  Netherlands (1)

Top investigators

Michael P Bokoch, M.D., Ph.D. (1)

Results publications

PMID 24466071, PMID 37984940

NIH funding

2025 (1)